BCRX BioCryst Pharmaceuticals Inc.

2.38
-0.12  -5%
Previous Close 2.5
Open 2.49
Price To Book -29.81
Market Cap 263,395,644
Shares 110,438,425
Volume 970,862
Short Ratio
Av. Daily Volume 1,446,503
Stock charts supplied by TradingView

NewsSee all news

  1. BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired

  2. U.S. Government Exercises Option for Additonal Rapivab® for Strategic National Stockpile

    RESEARCH TRIANGLE PARK, N.C., Sept. 26, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to

  3. BioCryst Pharmaceuticals to Present at Cantor Global Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Sept. 24, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Cantor Global Healthcare Conference in New York on

  4. BioCryst Appoints Helen Thackray, M.D., to Board of Directors

    RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company has appointed clinical rare disease expert, Helen Thackray, M.D., FAAP, to

  5. BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved September 21, 2017.
RAPIVAB (peramivir injection)
Acute uncomplicated influenza to pediatric patients
Phase 3 trial to commence 2020.
BCX7353
Angioedema attacks in patients with hereditary angioedema (HAE)
NDA filing due 4Q 2019.
BCX7353 - APeX-2
Reduce or eliminate attacks in HAE patients
Phase 2b data released February 2016 - primary endpoint not met
BCX4161 - OPuS-2
Hereditary angioedema
Approved Dec 22 2014
RAPIVAB (peramivir)
INFLUENZA ACUTE
Dosing of first patient in long-term safety trial announced February 28, 2018.
BCX7353 - APeX-S
Hereditary angioedema (HAE)
Phase 1 trial completion announced May 9, 2019. Generally safe and well tolerated.
Galidesivir
Healthy volunteers
Phase 1 data due 4Q 2019.
BCX9930
Healthy subjects
Phase 1 trial to commence 2H 2019.
BCX9250
Fibrodysplasia ossificans progressiva (FOP)

Latest News

  1. BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired

  2. U.S. Government Exercises Option for Additonal Rapivab® for Strategic National Stockpile

    RESEARCH TRIANGLE PARK, N.C., Sept. 26, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to

  3. BioCryst Pharmaceuticals to Present at Cantor Global Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Sept. 24, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Cantor Global Healthcare Conference in New York on

  4. BioCryst Appoints Helen Thackray, M.D., to Board of Directors

    RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company has appointed clinical rare disease expert, Helen Thackray, M.D., FAAP, to

  5. BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired

  6. BioCryst to Present at H.C. Wainwright Global Investment Conference

    RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the H.C. Wainwright Global Investment Conference in New